CDX
MM.1S
Tumor indication
Lymphoid
Tumor subtype
Multiple Myeloma
Description
MM.1S (Multiple Myeloma CDX Model)
The MM.1S multiple myeloma line was derived from plasma cell leukemia. Unlike its resistant counterpart, MM.1S is glucocorticoid-sensitive. It retains plasma cell biology, including immunoglobulin secretion. MM.1S is a widely used model for studying therapeutic response in multiple myeloma.
Key Features:
- Derived from plasma cell leukemia.
- Glucocorticoid-sensitive line.
- Produces immunoglobulin light chains.
- Tumorigenic in xenografts.
Applications:
MM.1S supports studies of glucocorticoid-based therapies in multiple myeloma. Researchers use it to compare with resistant lines for mechanism-of-resistance studies. It is applied in biomarker discovery and therapeutic testing. Its defined biology makes it a standard myeloma model.
Details
- Tumor indication
- Lymphoid
- Tumor subtype
- Multiple Myeloma
- Organism
- Human
- Mouse sex
- Female
- Lumin data
- RNA-Seq, WES
Mutated genes
Select a gene to see the variants recorded for this line.
Gene expression
Show all values
| Gene | Expression |
|---|
Expression measured across the Champions panel.
Request this cell line
Let's build the right study, together.
Backed by deep expertise in these models, our team will work with you to design the study around your target, line of therapy, and endpoint.